Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Promedior
371 Phoenixville Pike
Malvern, PA 19355
Phone: 610-560-1435

Promedior is a clinical-stage biotechnology company developing a pipeline of novel Pentraxin-2 therapeutics for the treatment of fibrovascular diseases. Pentraxin-2 therapeutics treat fibrovascular diseases by naturally regulating monocyte-derived cells (macrophages and fibrocytes) that control the fibrotic process and drive pathologic neovascularization. Based on a unique mechanism of action, Pentraxin-2 localizes to sites of tissue damage and stimulates monocytes to differentiate into regulatory macrophages rather than pro-fibrotic macrophages and fibrocytes, thereby reversing inflammatory, fibrotic and neovascular processes and promoting normal healing. By acting upstream of these pathologic processes using a natural regulatory pathway, Pentraxin-2 therapeutics provide a superior therapeutic approach and an inherently safer profile. 

Key Contact
Name
Dominick C. Colangelo
Title
President & CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
Valuation
03/08/12 $21,500,000 Series D Easton Capital
Fibrotec Ventures
Forbion Capital Partners
Healthcare Ventures
Polaris Partners
undisclosed
10/15/12 $24,500,000 Series D Easton Capital
Fibrotec Ventures
Forbion Capital Partners
Healthcare Ventures
Polaris Partners
Shire Strategic Investment Group
undisclosed